Celgene Announces IMiD Combination Therapies form Backbone of Multiple Myeloma Research at #ASH2015

Celgene Corporation

today announced that nearly 30 combination studies including IMiD® compounds, REVLIMID® (lenalidomide) and POMALYST®/IMNOVID® (pomalidomide), across a range of patient segments within multiple myeloma are being presented at the 57th American Society of Hematology Annual Meeting (ASH). In the U.S., REVLIMID in combination with dexamethasone is approved for patients with multiple myeloma and POMALYST in combination with dexamethasone is approved for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. These treatments are the subject of important investigational studies in combination with